Sansure Biotech Inc. (SHA:688289)

Market Cap	9.30B -13.7%
Revenue (ttm)	1.60B +3.9%
Net Income	156.94M -45.2%
EPS	0.26 -46.3%
Shares Out	574.18M
PE Ratio	61.65
Forward PE	37.10
Dividend	0.54 (3.23%)
Ex-Dividend Date	n/a

Volume	3,838,254
Open	16.53
Previous Close	16.64
Day's Range	16.12 - 16.73
52-Week Range	16.13 - 23.45
Beta	0.55
Analysts	Strong Buy
Price Target	22.02 (+35.93%)
Earnings Date	Apr 30, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2008
• Employees: 2,409
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688289

Financial Performance

In 2025, Sansure Biotech's revenue was 1.64 billion, an increase of 12.58% compared to the previous year's 1.46 billion. Earnings were 198.94 million, a decrease of -27.82%.